Trial Profile

Open-label Study Investigating Efficacy, Safety and Pharmacokinetics of Concizumab Prophylaxis in Children Below 12 Years With Haemophilia A or B With or Without Inhibitors

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 08 Sep 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Concizumab (Primary)
Indications Haemophilia A; Haemophilia B
Focus Adverse reactions; Expanded access; Registrational
Acronyms Explorer10
Sponsors Novo Nordisk; Novo Nordisk Foundation

Most Recent Events

11 Jul 2026 Result were presented at the International Society on Thrombosis and Haemostasis (ISTH) Congress in Paris, according to the Novo Nordisk Media Release.
11 Jul 2026 Results presented in the Novo Nordisk Media Release.
26 Jun 2026 According to Novo Nordisk media release, new data will be presented at the upcoming International Society on Thrombosis and Haemostasis (ISTH) Congress, July 11-15 in Paris, France.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com